Background: As breast cancer survivorship has increased, so has an awareness of the
Introduction
Breast cancer remains the most common cancer among women. Early detection and treatment is decreasing cancer-associated mortality but increasing post-treatment morbidity.
Over 80% of newly diagnosed breast cancer patients are predicted to survive five years. [1] As breast cancer survivorship increases, clinicians are gaining awareness of the associated morbidities that impact daily life and learning to predict and prevent these morbidities, which is vital to improving the quality of life of breast cancer survivors. [2, 3] Breast cancer-related lymphedema (BCRL) is one such morbidity that affects an estimated 6-30% of survivors. [4, 5] BCRL has been linked to body mass index (BMI), mastectomy, axillary dissection, axillary radiation, and lymph node status. [4, [6] [7] [8] [9] [10] [11] [12] [13] Most studies have focused on patients who undergo mastectomy for primary cancer treatment. [14] The goal of recent studies has been to assess the extent of axillary damage and compare rates of lymphedema with or without radiation therapy, sentinel lymph node biopsy (SLNB), and/or axillary lymph node dissection (ALND). [11, 12, [15] [16] [17] As cancer treatments increase survival, patients are pursuing breast reconstruction and becoming more aware of their available reconstructive options. It is possible that reconstructive surgical interventions in the mastectomy or axillary field could alter the risk of developing BCRL. Studies addressing this concern have found no increased incidence of lymphedema due to reconstructive surgery, and limited retrospective data indicate that delayed autologous breast reconstruction may reduce the severity of existing lymphedema. [18, 19] However, no control groups of mastectomy-only patients were included in those studies.
The primary goal of this study was to compare the incidences of BCRL in patients who undergo mastectomy and reconstruction versus those treated with mastectomy alone and to address the question of whether immediate breast reconstruction has a beneficial effect in reducing the incidence of lymphedema. Our secondary goal was to identify the independent variables affecting the incidence and time to development of BCRL when axillary interventions Copyright @ American Society of Plastic Surgeons. All rights reserved.
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are cross-matched and controlled. To the best of our knowledge, this is the first study to do a direct cohort comparison of BCRL incidence in patients who did and did not undergo reconstruction after mastectomy.
Methods
Following internal institutional review board approval, two independent, secure, and prospectively maintained departmental databases were searched to identify all consecutive female breast cancer patients who underwent therapeutic mastectomy over a 6-year period from Center. The Department of Plastic Surgery database identified patients who underwent mastectomy and reconstruction, and the Department of Surgical Oncology database identified patients who underwent mastectomy alone. These databases were cross-referenced to remove any duplication of individuals. Patients were excluded if they had missing data for pertinent variables, lymphedema (LE) prior to mastectomy or at presentation, edema that occurred within 2 weeks of surgery and resolved within 30 days, or a history of preoperative radiation therapy (RT) or were lost to follow-up within 6 months of surgery. To reduce variation of potential factors inducing bias between the two populations from the queried databases, the two data groups or cohorts were cross-matched for age (+/-5 years), postoperative RT, and SLND +/-ALND to obtain our study population for evaluation of BCRL incidence. Information regarding patient demographics, axillary intervention, and oncologic treatments was obtained from the prospectively maintained databases and validated by individual patient medical record review by a postdoctoral research fellow. The following patient characteristics were recorded: age, BMI, race, comorbidities, oncologic neoadjuvant and adjuvant treatments, type of axillary intervention and number of lymph nodes removed. All patients had at least 3 years of follow-up to capture the development of BCRL in the majority of the patients. BCRL was diagnosed using subjective Copyright @ American Society of Plastic Surgeons. All rights reserved. data that were documented in the prospective database. All cases of BCRL were reviewed and confirmed on the basis of objective data (e.g., arm circumference measurements) that were documented by designated health care providers in the medical record. Axillary interventions were classified as sentinel lymph node dissection (SLND), axillary lymph node dissection (ALND), ALND with or without SLND, or postoperative axillary RT.
Means and standard deviations were used to summarize continuous variables.
Frequencies and proportions were used to present the categorical clinical characteristics. A correlated logistic regression model was used to test associations between incidence of BCRL and demographic or clinical characteristics. SAS GENMOD procedures were used to calculate the odds ratios (ORs). Time to lymphedema was defined as the time interval from mastectomy date to BCRL diagnosis date or last follow-up date, whichever occurred first. Patients who had not developed BCRL at the time of last follow-up were censored in the analyses. The incidence rates of BCRL over time were estimated by the Kaplan-Meier product-limit method. KaplanMeier curves were used to present BCRL incidence over time for patients in each subgroup.
Univariate and multivariate Cox proportional hazard (Cox PH) regression models were used to estimate the hazard ratios (HRs) of predictors. The robust sandwich estimate method was used to analyze the clustered time-to-event data. The SAS command "proportionality test" was applied to test the proportionality assumption of Cox PH models. The significant or marginally significant factors in univariate models were the candidates to fit a multivariate model. The backward model selection method was used to construct the most parsimonious model. All tests were two-sided. A p value of <0.05 was considered significant. All analyses were performed in SAS 9.2 (SAS Institute Inc., Cary, NC) and R (The R Foundation for Statistical Computing).
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Results
Over the 6-year study period 1080 patients were identified in the plastic surgery database and 1596 in the surgical oncology database. After cross-matching, 576 pairs remained.
Following individual record review, two pairs were excluded because one or both patients had poorly determined BCRL status. The final data set included 574 pairs, or 1148 breasts, overall.
The average follow-up was 59 ± 26.9 months.
The total number of patients was 1090, with 58 undergoing bilateral therapeutic mastectomies. The average age was 55 years (range, 25-83 years). The average BMI at surgery was 27.2 kg/m 2 . Seven hundred and eighty-two (72%) of the 1090 patients were white and 79%
were non-smokers. When patient characteristics based on reconstruction status were analyzed, some differences between the two study groups became evident (Table 1b) . In 94.6% of the breasts studied, at least one type of surgical axillary intervention was performed. Of the reconstructive breasts, 280 breasts had tissue expander reconstruction, 41 had latissimus dorsi myocutaneous flaps with implants, and 253 had free autologous abdominal tissue only (Table 2 ).
Eleven percent of the breasts were treated with post-operative RT. Both of these parameters were matched between the data sets and did not differ significantly between the reconstruction and no reconstruction groups. Positive lymph nodes were strongly associated with mastectomy-only cases (p<0.001). BCRL developed in 78 (6.8%) of the 1148 breasts: 21 (3.7%) in the reconstructed and 57 (9.9%) in the mastectomy-only group (p<0.001) ( Table 2 ).
Univariate logistic regression modeling elucidated that patients who underwent reconstruction had a lower BCRL risk than patients who underwent mastectomy alone (OR=0.34, 95% CI=0.20-0.57, p<0.001, Multivariate logistic regression showed that reconstruction status, post-operative radiation therapy, BMI, and positive lymph nodes were all significant independent variables for the development of BCRL (Table 3b ). After adjusting for factors significantly predictive of breast reconstruction, including BMI, breast reconstruction was associated with a statistically significant lower incidence of BCRL development (adjusted OR=0.37). Axillary intervention
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(SLND vs ALND+/-SLND) was a candidate for assessment in the multivariate model but was not significant as an independent variable for the development of BCRL after stronger factors were included.
A univariate CoxPH regression model of time to BCRL development showed that patients who underwent breast reconstruction developed BCRL significantly more slowly than mastectomy-alone patients (HR=0.39, 95% CI=0.23-0.65, p<0.001, Table 4a ). Breast reconstruction subgroups were not independently associated with differences in time to BCRL development. Table 4b shows the multivariate Cox PH regression model of time to development of BCRL. Post-operative RT (p<0.001), positive lymph nodes (p=0.026), and higher BMI (p=0.040) were all significant independent variables associated with earlier development of BCRL. Pre-operative chemotherapy and axillary intervention were not significantly associated with increased time to BCRL after multivariate analysis. Breast reconstruction was significantly associated with delayed development of BCRL after adjusting for other significant predictors (adjusted HR=0.44, 95% CI=0.267-6.87, p=0.002). Figure 1 shows the incidence of BCRL by breast reconstruction status over time.
A C C E P T E D Discussion
Increased breast cancer survivorship directly translates into increased longevity and the subsequently higher impact of cancer-related morbidity. BCRL is a debilitating disease that leads to pain, recurrent infections, disability, and an overall reduced quality of life. [20] [21] [22] Many breast cancer patients choose to undergo delayed or immediate breast reconstruction to improve their body image and/or the fit of clothing. Recent studies have started to show that there is little or no increased risk of BCRL with subsequent reconstruction. [18, 19] This is the first study to do a direct cohort comparison between patients who underwent mastectomy plus reconstruction versus mastectomy alone. We found that reconstruction was associated with a lower rate of BCRL (9.9% vs. 3.7%) and a delayed onset when compared to mastectomy alone. Our study points to the possibility that reconstruction may have some type of protective effect with respect to the development of BCRL.
Among the possible reasons why reconstruction may be beneficial is that transferred vascularized tissue can bridge damaged lymphatics, as well as reduce scarring following lymph node dissection. [18, [23] [24] [25] [26] [27] In addition, vascularized tissue has the potential to restore lymphatic flow by promoting angiogenesis and lymphatic regeneration. [28, 29] Evidence of lymphatic regeneration and spontaneous re-anastomosis with recipient vessels has been demonstrated, and these events are linked to patterns of vascular endothelial growth factor expression and macrophage infiltration. [30] In addition, there is evidence to demonstrate that the process of tissue expansion and capsule formation, which induces tissue ischemia, results in increased expression of VEGF. [31] As a result of this increased VEGF expression, tissue angiogenesis, and potentially lymphangiogenesis, may reduce the incidence of lymphedema even in patients who undergo reconstruction with tissue expanders followed by implants because of the process of continued ischemia and capsular formation. [32] Recent advances in the transfer of lymph nodes as vascularized tissue flaps or in combination with a microvascular breast
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reconstruction are showing promise and may offer more insight into the molecular mechanisms of lymphangiogenesis and its role in preventing BCRL. [33] [34] [35] [36] Recently, lymphedema research exploring the unique biology of the lymph system has pointed towards variability in function or underlying genetics as a causative factor in the development of BCRL. [37] [38] [39] [40] [41] [42] Some women who develop BCRL may have lymphatic abnormalities, such as a weaker lymphatic pump or increased lymph flow (or afterload), that predispose them to the development of BCRL. [40] It is also interesting to note that in our study, cross-matched patients undergoing mastectomy without reconstruction had significantly higher rates of diabetes mellitus, hypertension, and smoking. These patients were also more likely to be overweight or obese. Could these morbidities lead to changes in lymphatic flow and predispose women who are diagnosed with breast cancer to develop lymphedema? Alternatively, these factors may result in self-selection or physician bias in the process to determine whether patients undergo reconstructive surgery. [43] A major criticism of lymphedema incidence studies is the criteria used in the diagnosis and description of lymphedema. Currently, there is no gold standard measure or defining criteria for lymphedema assessment in the clinical setting. [44] Objective measurements are nonstandardized and can vary widely. [45] Imaging techniques may provide valuable information but are limited to a select population and not used routinely for diagnosis. [45, 46] 
rate of almost 1% per year. [48] Therefore, despite our almost 5-year follow-up, a few patients not captured in our analysis may still develop BCRL due to infections, trauma, or weight gain.
Many factors have been blamed for increasing the risk of BCRL. [13] The literature irrefutably supports that axillary clearance and/or axillary radiation increases BCRL incidence. [6, [49] [50] [51] [52] [53] In our study, we controlled for these known factors by exact cross-matching of our two patient populations. Patient age was matched within a range of +/-5 years, which is the most common method of cross-matching for continuous variables. Advanced age has been suggested to be a significant factor in the development of lymphedema. [9, 54, 55] One variable not controlled for in our comparison was weight, or BMI. Although higher BMI is known to increase the risk of developing BCRL [7, 9, 15, 48, 56] , a methodological decision was made to only cross-match for three variables in order to maintain adequate numbers for analysis. On multivariate analysis, our study showed BMI as a significant independent variable in the overall development and time of onset of lymphedema. By adjusting the BMI in the multivariate model, we eliminated the potential for BMI to confound our analysis and demonstrated that breast reconstruction patients, regardless of BMI, had a lower rate of lymphedema. In addition, breast reconstruction was found to be significantly associated with delayed development of lymphedema, after adjusting for other significant predictors on multivariate analysis. Additional long-term studies and prospective studies to evaluate BCRL incidence in patients undergoing reconstruction are necessary, as are improved objective measurements of BCRL, to further demonstrate the potential benefit of breast reconstruction in BCRL prevention.
Conclusion
Patients who undergo breast reconstruction have a lower incidence and later onset of BCRL compared to patients who undergo mastectomy alone when cross-matched for age, axillary RT, and surgical axillary interventions.
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